U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249112) titled 'DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD' on Nov. 17.
Brief Summary: The Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease globally, with a prevalence exceeding 30% in the population. MASLD is strictly associated with insulin resistance and cardiometabolic conditions, and in 20-30% of cases, it can progress to steatohepatitis (MASH), which is characterized by progressive liver damage and inflammation. In patients at higher risk, the disease can lead to the onset of advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). One of the main problems in the clinical ...